Aprecia snags first FDA approval for a 3-D printed drug

The FDA has given the go-ahead for a small Pennsylvania company to launch the first drug made using three-dimensional printing. Aprecia Pharmaceuticals says on Monday the FDA approved Spritam, a formulation of epilepsy drug levetiracetam that uses the 3-D process to create a porous pill that rapidly disintegrates with a sip of liquid. "By combining 3DP technology with a highly-prescribed epilepsy treatment, Spritam is designed to fill a need for patients who struggle with their current medication experience," Aprecia CEO Don Wetherhold said in a statement. The company, which is building a plant to make the drug, plans to develop more highly prescribed, high-dose medications. Story | Release

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.